Atara Biotherapeutics (NASDAQ:ATRA) will be announcing its earnings results before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of ($1.45) per share for the quarter.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.44) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.48) by $0.04. On average, analysts expect Atara Biotherapeutics to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Shares of NASDAQ:ATRA opened at $12.87 on Friday. Atara Biotherapeutics has a twelve month low of $12.78 and a twelve month high of $43.95. The stock has a 50 day simple moving average of $18.15. The company has a current ratio of 9.96, a quick ratio of 9.96 and a debt-to-equity ratio of 0.05. The firm has a market cap of $661.00 million, a P/E ratio of -2.44 and a beta of 2.09.
ATRA has been the topic of several research reports. Stifel Nicolaus initiated coverage on shares of Atara Biotherapeutics in a report on Wednesday, May 22nd. They issued a “buy” rating and a $41.00 price target on the stock. Roth Capital initiated coverage on shares of Atara Biotherapeutics in a report on Thursday, May 30th. They issued a “buy” rating and a $30.00 price target on the stock. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 16th. Cowen reiterated a “buy” rating on shares of Atara Biotherapeutics in a report on Tuesday, July 16th. Finally, ValuEngine downgraded shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 17th. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $41.86.
In other news, CEO Isaac E. Ciechanover sold 5,850 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $23.09, for a total transaction of $135,076.50. Following the sale, the chief executive officer now owns 332,243 shares of the company’s stock, valued at approximately $7,671,490.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Joe Newell sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $35.00, for a total transaction of $52,500.00. Following the sale, the insider now directly owns 62,998 shares in the company, valued at approximately $2,204,930. The disclosure for this sale can be found here. In the last quarter, insiders sold 15,150 shares of company stock worth $379,535. 7.00% of the stock is owned by corporate insiders.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Featured Article: What is systematic risk?
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.